×
Components:
Sodium Polysteyrene Sulfonate
Method of action:
All Other Therapeutic Products
Available in countries
See all
close
Medically reviewed by Fedorchenko Olga Valeryevna, Pharmacy-Provisor. Last updated on 2019.12.07

Name of the medicinal product

Kionex

Qualitative and quantitative composition

Sodium Polysteyrene Sulfonate

Pharmaceutical form

Powder; Suspension

Therapeutic indications

The information provided in Therapeutic indications of Kionex is based on data of another medicine with exactly the same composition as the Kionex of the medicine (Sodium Polysteyrene Sulfonate). Be careful and be sure to specify the information on the section Therapeutic indications in the instructions to the drug Kionex directly from the package or from the pharmacist at the pharmacy.
more... close

Kionex is indicated for the treatment of hyperkalemia.

Limitation Of Use

Kionex should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

Dosage (Posology) and method of administration

The information provided in Dosage (Posology) and method of administration of Kionex is based on data of another medicine with exactly the same composition as the Kionex of the medicine (Sodium Polysteyrene Sulfonate). Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug Kionex directly from the package or from the pharmacist at the pharmacy.
more... close

General Information

Administer Kionex at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation

Recommended Dosage

The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia.

Oral

The average total daily adult dose of Kionex is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily.

Rectal

The average adult dose is 30 g to 50 g every six hours.

Preparation And Administration

Prepare suspension fresh and use within 24 hours.

Do not heat Kionex as it could alter the exchange properties of the resin.

One level teaspoon contains approximately 3.5 g of Kionex and 15 mEq of sodium.

Oral Suspension

Suspend each dose in a small quantity of water or syrup, approximately 3 to 4 mL of liquid per gram of resin. Administer with patient in an upright position.

Enema

After an initial cleansing enema, insert a soft, large size (French 28) rubber tube into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and tape in place.

Administer as a warm (body temperature) emulsion in 100 mL of aqueous vehicle and flush with 50 to 100 ml of fluid. A somewhat thicker suspension may be used, but do not form a paste.

Agitate the emulsion gently during administration. The resin should be retained for as long as possible and follow by a cleansing enema with a nonsodium containing solution. Ensure an adequate volume of cleansing solution (up to 2 liters) is utilized.

Contraindications

The information provided in Contraindications of Kionex is based on data of another medicine with exactly the same composition as the Kionex of the medicine (Sodium Polysteyrene Sulfonate). Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug Kionex directly from the package or from the pharmacist at the pharmacy.
more... close

Kionex is contraindicated in patients with the following conditions:

  • Hypersensitivity to polystyrene sulfonate resins
  • Obstructive bowel disease
  • Neonates with reduced gut motility

Special warnings and precautions for use

The information provided in Special warnings and precautions for use of Kionex is based on data of another medicine with exactly the same composition as the Kionex of the medicine (Sodium Polysteyrene Sulfonate). Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug Kionex directly from the package or from the pharmacist at the pharmacy.
more... close

WARNINGS

Included as part of the PRECAUTIONS section.

PRECAUTIONS

Intestinal Necrosis

Cases of intestinal necrosis, some fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with Kionex use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of sorbitol is not recommended.

  • Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery.
  • Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction). Discontinue use in patients who develop constipation.

Electrolyte Disturbances

Monitor serum potassium during therapy because severe hypokalemia may occur.

Kionex is not totally selective for potassium, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Monitor calcium and magnesium in patients receiving Kionex.

Fluid Overload In Patients Sensitive To High Sodium Intake

Each 15 g dose of Kionex contains 1500 mg (60 mEq) of sodium. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, edema) for signs of fluid overload. Adjustment of other sources of sodium may be required.

Risk Of Aspiration

Cases of acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles have been reported. Patients with impaired gag reflex, altered level of consciousness, or patients prone to regurgitation may be at increased risk. Administer Kionex with the patient in an upright position.

Binding To Other Orally Administered Medications

Kionex may bind orally administered medications, which could decrease their gastrointestinal absorption and lead to reduced efficacy. Administer other oral medications at least 3 hours before or 3 hours after Kionex. Patients with gastroparesis may require a 6 hour separation..

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment Of Fertility

Studies have not been performed.

Use In Specific Populations

Pregnancy

Risk Summary

Kionex is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk.

Lactation

Risk Summary

Kionex is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant.

Pediatric Use

Studies of safety and efficacy have not been conducted in pediatric patients.

In pediatric patients, as in adults, Kionex is expected to bind potassium at the practical exchange ratio of 1mEq potassium per 1 gram of resin.

In neonates, Kionex should not be given by the oral route. In both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. Premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with Kionex. use.

Undesirable effects

The information provided in Undesirable effects of Kionex is based on data of another medicine with exactly the same composition as the Kionex of the medicine (Sodium Polysteyrene Sulfonate). Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug Kionex directly from the package or from the pharmacist at the pharmacy.
more... close

The following adverse reactions are discussed elsewhere in the labeling:

  • Intestinal Necrosis
  • Electrolyte Disturbances
  • Aspiration

The following adverse reactions have been identified during post-approval use of Kionex. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.

Gastrointestinal: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, ulcerations, vomiting, gastric irritation, intestinal obstruction (due to concentration of aluminium hydroxide)

Metabolic: systemic alkalosis

Overdose

The information provided in Overdose of Kionex is based on data of another medicine with exactly the same composition as the Kionex of the medicine (Sodium Polysteyrene Sulfonate). Be careful and be sure to specify the information on the section Overdose in the instructions to the drug Kionex directly from the package or from the pharmacist at the pharmacy.
more... close

Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas.

Pharmacodynamic properties

The information provided in Pharmacodynamic properties of Kionex is based on data of another medicine with exactly the same composition as the Kionex of the medicine (Sodium Polysteyrene Sulfonate). Be careful and be sure to specify the information on the section Pharmacodynamic properties in the instructions to the drug Kionex directly from the package or from the pharmacist at the pharmacy.
more... close

The effective lowering of serum potassium with Kionex may take hours to days.

Pharmacokinetic properties

The information provided in Pharmacokinetic properties of Kionex is based on data of another medicine with exactly the same composition as the Kionex of the medicine (Sodium Polysteyrene Sulfonate). Be careful and be sure to specify the information on the section Pharmacokinetic properties in the instructions to the drug Kionex directly from the package or from the pharmacist at the pharmacy.
more... close

The in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent; hence, about one third of the resin's actual sodium content is delivered to the body.

Kionex is not absorbed systemically.

Site feedback

How easy to use our site?

Commentary is required, without it we won't know how to become better
The maximum length of review is 1000 symbols

Thanks!

You help us to become better